NeuroBo Pharmaceuticals’ DA-1726 shows promising results in pre-clinical obesity treatment studies
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology firm, announced promising pre-clinical data for DA-1726, a novel oxyntomodulin (OXM) analog functioning as a dual agonist of glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The data was presented at the American Diabetes Association’s 84th Scientific Sessions in Orlando, Florida.
The pre-clinical studies showcased DA-1726’s superiority over survodutide, another drug with a similar mechanism, in various metrics including weight loss, lean body mass retention, and lipid-lowering effects. Hyung Heon Kim, President and CEO of NeuroBo, highlighted the distinctive capabilities of DA-1726, stating, “DA-1726 demonstrated superior weight loss and retention of relative lean body mass preservation compared to survodutide, further distinguishing it from other obesity drugs in its class.”
Presented by Tae-Hyoung Kim from the Dong-A ST Research Center, the study revealed that DA-1726 significantly reduced cholesterol levels and induced superior weight loss in obese mouse models. Notably, DA-1726 also showed promising results in lowering glucose levels more effectively than survodutide. These results support the potential of DA-1726 as a best-in-class obesity drug with a superior efficacy and tolerability profile.
NeuroBo is currently advancing DA-1726 through Phase 1 clinical trials, with expectations to dose the first patient in the multiple ascending dose (MAD) Part 2 and announce top-line data from the single ascending dose (SAD) Part 1 within the third quarter of this year. The top-line data from the MAD Part 2 is anticipated in the first quarter of 2025.
DA-1726’s differentiated impact stems from its dual agonist activity at GLP-1 and glucagon receptors, enhancing energy expenditure and improving cholesterol metabolism. This unique action not only positions DA-1726 for effectiveness in obesity treatment but also in managing Metabolic Dysfunction-Associated Steatohepatitis (MASH).
The promising outcomes of DA-1726 suggest a significant advancement in the treatment of obesity and related metabolic disorders. Its ability to achieve superior results while maintaining lean body mass and reducing lipid levels could revolutionize obesity pharmacotherapy, offering patients more effective and tolerable treatment options.